Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872099 | 0.97 | FKBP1A (0.84) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL437462 | 0.95 | FKBP1A (0.90) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL13492311 | 0.95 | FKBP1A (0.86) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL439484 | 0.94 | ABCB11 (0.88) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL436555 | 0.94 | ABCB11 (0.88) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL469099 | 0.94 | FKBP1A (0.90) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL13652583 | 0.94 | FKBP1A (0.92) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL13524343 | 0.94 | FKBP1A (0.92) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL437518 | 0.94 | FKBP1A (0.92) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL15872107 | 0.93 | FKBP1A (0.77) | FKBP1AMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778636-B2 | Chemo-enzymatic approach to the synthesis of pimecrolimus | EUTICALS S.P.A. (IT) | 2014-07-15 | — | — | US | disclosed |
| US-20120064575-A1 | CHEMO-ENZYMATIC APPROACH TO THE SYNTHESIS OF PIMECROLIMUS | AMRI ITALY S.R.L. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120064575-A1 | CHEMO-ENZYMATIC APPROACH TO THE SYNTHESIS OF PIMECROLIMUS | AMRI ITALY S.R.L. (IT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064575-A1 | CHEMO-ENZYMATIC APPROACH TO THE SYNTHESIS OF PIMECROLIMUS | CYP51A1, PIM1, COASY | FKBP1A 1571/4885MEN1 2634/4885LMNA 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.